Activated Protein MAP Kinase Inhibitors

The cascade of apoptosis may be promoted by mitogen activated protein (MAP) kinase activation. CEP1347, a small molecule MAP kinase inhibitor that crosses the blood brain barrier is protective in MPTP-treated mice (Saporito et al., 1999). A clinical trial showed good tolerability, no interference with L-dopa pharmacokinetics, and no symptomatic effects of treatment over a 4-week period (Parkinson Study Group, 2004). A larger phase II trial has commenced. 

---